David Mischoulon, a prominent psychiatrist at Massachusetts General Hospital and Harvard Medical School, delves into the intriguing world of Cannabidiol (CBD) and its psychiatric applications. He discusses its potential benefits for disorders like social anxiety and schizophrenia, highlighting the importance of scientific evidence over hype. Mischoulon emphasizes cautious usage, the mechanisms behind CBD, and real-world case studies demonstrating its therapeutic effects. Is CBD the future of mental health treatment or just a trend?

David Mischoulon, Director of the Depression Clinical and Research Program at Massachusetts General Hospital, dives into the intriguing world of Ashwagandha, a natural remedy with roots in ancient medicine. He discusses its potential in treating anxiety, depression, and OCD, highlighting its promise for patients resistant to conventional treatments. Mischoulon also emphasizes the importance of personalized approaches and careful monitoring when using Ashwagandha, drawing from recent research and clinical insights to inform best practices.

David Mischoulon, Director of the Depression Clinical and Research Program at Massachusetts General Hospital, discusses the promise of N-acetylcysteine (NAC) in treating mood disorders. He explores how NAC protects brain cells and its potential advantages over traditional medications, particularly regarding side effects. The conversation dives into compelling clinical trial evidence linking NAC to improved outcomes in depression and bipolar disorder, highlighting its appeal as a non-pharmaceutical alternative for both adults and children.